152 related articles for article (PubMed ID: 22113929)
1. Cost analysis of re-exploration for bleeding after coronary artery bypass graft surgery.
Alström U; Levin LÅ; Ståhle E; Svedjeholm R; Friberg O
Br J Anaesth; 2012 Feb; 108(2):216-22. PubMed ID: 22113929
[TBL] [Abstract][Full Text] [Related]
2. Administration of recombinant activated factor VII in the intensive care unit after complex cardiovascular surgery: clinical and economic outcomes.
Uber WE; Toole JM; Stroud MR; Haney JS; Lazarchick J; Crawford FA; Ikonomidis JS
J Thorac Cardiovasc Surg; 2011 Jun; 141(6):1469-77.e2. PubMed ID: 21457998
[TBL] [Abstract][Full Text] [Related]
3. Multicentre randomized clinical trial to investigate the cost-effectiveness of an allogeneic single-donor fibrin sealant after coronary artery bypass grafting (FIBER Study).
Tavilla G; Bruggemans EF; Gielen CL; Brand A; van den Hout WB; Klautz RJ; van Hilten JA
Br J Surg; 2015 Oct; 102(11):1338-47. PubMed ID: 26265447
[TBL] [Abstract][Full Text] [Related]
4. Cost analysis of aprotinin for coronary artery bypass patients: analysis of the randomized trials.
Smith PK; Datta SK; Muhlbaier LH; Samsa G; Nadel A; Lipscomb J
Ann Thorac Surg; 2004 Feb; 77(2):635-42; discussion 642-3. PubMed ID: 14759451
[TBL] [Abstract][Full Text] [Related]
5. Impact on postoperative bleeding and cost of recombinant activated factor VII in patients undergoing heart transplantation.
Hollis AL; Lowery AV; Pajoumand M; Pham SM; Slejko JF; Tanaka KA; Mazzeffi M
Ann Card Anaesth; 2016; 19(3):418-24. PubMed ID: 27397445
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling.
Ballal RD; Botteman MF; Foley I; Stephens JM; Wilke CT; Joshi AV
Curr Med Res Opin; 2008 Mar; 24(3):753-68. PubMed ID: 18234151
[TBL] [Abstract][Full Text] [Related]
7. Re-exploration for bleeding associated with increased incidence of the need for reintervention after coronary artery bypass graft surgery.
Dimberg A; Alström U; Janiec M
Interact Cardiovasc Thorac Surg; 2019 Feb; 28(2):214-221. PubMed ID: 30101308
[TBL] [Abstract][Full Text] [Related]
8. Individual surgeon's impact on the risk of re-exploration for excessive bleeding after coronary artery bypass surgery.
Biancari F; Mikkola R; Heikkinen J; Lahtinen J; Kettunen U; Juvonen T
J Cardiothorac Vasc Anesth; 2012 Aug; 26(4):550-6. PubMed ID: 22498634
[TBL] [Abstract][Full Text] [Related]
9. Use of a flowable haemostat versus an oxidised regenerated cellulose agent in primary elective cardiac surgery: economic impact from a UK healthcare perspective.
Joshi MR; Latham J; Okorogheye G
J Cardiothorac Surg; 2017 Nov; 12(1):107. PubMed ID: 29187216
[TBL] [Abstract][Full Text] [Related]
10. Myocardial infarction following coronary artery bypass graft surgery increases healthcare resource utilization.
Chen JC; Kaul P; Levy JH; Haverich A; Menasché P; Smith PK; Carrier M; Verrier ED; Van de Werf F; Burge R; Finnegan P; Mark DB; Shernan SK;
Crit Care Med; 2007 May; 35(5):1296-301. PubMed ID: 17414091
[TBL] [Abstract][Full Text] [Related]
11. Coronary artery bypass grafting in diabetics: A growing health care cost crisis.
Raza S; Sabik JF; Ainkaran P; Blackstone EH
J Thorac Cardiovasc Surg; 2015 Aug; 150(2):304-2.e2. PubMed ID: 26027913
[TBL] [Abstract][Full Text] [Related]
12. Coronary artery bypass graft surgery in acute coronary syndrome: incidence, cost impact, and acute clopidogrel interruption.
Johnston SS; Bell K; Gdovin J; Jing Y; Graham J
Hosp Pract (1995); 2012 Feb; 40(1):15-23. PubMed ID: 22406879
[TBL] [Abstract][Full Text] [Related]
13. Clopidogrel administration prior to coronary artery bypass grafting surgery: the cardiologist's panacea or the surgeon's headache?
Kapetanakis EI; Medlam DA; Boyce SW; Haile E; Hill PC; Dullum MK; Bafi AS; Petro KR; Corso PJ
Eur Heart J; 2005 Mar; 26(6):576-83. PubMed ID: 15723815
[TBL] [Abstract][Full Text] [Related]
14. [Our experience with recombinant activated factor VII (NovoSeven) in the high risk cardiosurgical patients with bleeding complication].
Miskolczi S; Vaszily M; Papp C; Péterffy A
Magy Seb; 2008; 61 Suppl():45-7. PubMed ID: 18504237
[TBL] [Abstract][Full Text] [Related]
15. Cost/benefit analysis of pharmacologic hemostasis.
Harmon DE
Ann Thorac Surg; 1996 Feb; 61(2 Suppl):S21-5; discussion S33-4. PubMed ID: 8572828
[TBL] [Abstract][Full Text] [Related]
16. The effect on costs of the use of half-dose aprotinin for first-time reoperative coronary artery bypass patients.
Able ME; Tilly DA
Clin Ther; 1998; 20(3):581-91. PubMed ID: 9663372
[TBL] [Abstract][Full Text] [Related]
17. Aprotinin in cardiac surgery patients: is the risk worth the benefit?
Stamou SC; Reames MK; Skipper E; Stiegel RM; Nussbaum M; Geller R; Robicsek F; Lobdell KW
Eur J Cardiothorac Surg; 2009 Nov; 36(5):869-75. PubMed ID: 19782574
[TBL] [Abstract][Full Text] [Related]
18. A model of the direct and indirect effects of aprotinin administration on the overall costs of coronary revascularization surgery in a university teaching hospital cardiothoracic unit.
Robinson D; Bliss E
Clin Ther; 2002 Oct; 24(10):1677-89. PubMed ID: 12462296
[TBL] [Abstract][Full Text] [Related]
19. Cost and effectiveness of treatments for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Korea.
You CW; Lee SY; Park SK
Haemophilia; 2009 Jan; 15(1):217-26. PubMed ID: 18754800
[TBL] [Abstract][Full Text] [Related]
20. Does clopidogrel increase blood loss following coronary artery bypass surgery?
Chu MW; Wilson SR; Novick RJ; Stitt LW; Quantz MA
Ann Thorac Surg; 2004 Nov; 78(5):1536-41. PubMed ID: 15511426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
